GO
Loading...

Enter multiple symbols separated by commas

Stocks Express Scripts Holding Co

More

  • NEW YORK, March 30- UnitedHealth Group Inc's planned takeover of No. 4 U.S. pharmacy benefits provider Catamaran Corp will give the companies added heft in price talks with drug companies, serving as a catalyst for deals allowing other insurers to bulk up. The $12.8 billion deal comes at a time when Wall Street has been parsing the possibilities that top insurers...

  • New cholesterol drugs cut heart attack risk in half Monday, 16 Mar 2015 | 8:44 AM ET
    Amgen

    Studies of a new class of cholesterol-lowering drugs signal that they can reduce by half the risk of heart attack.

  • An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...

  • These cholesterol drugs stocks are poised to move Friday, 13 Mar 2015 | 3:33 PM ET
    Surgeons performing operation

    Here are the stocks to watch heading out of this weekend's American College of Cardiology conference in San Diego.

  • CVS: Copycat drugs may bring price cuts of 40-50% Thursday, 12 Mar 2015 | 7:14 AM ET

    Copycat biotech drugs in the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, said a top CVS Health exec.

  • WASHINGTON, March 11- The entry of copycat biotech drugs into the U.S. market could cut prices of expensive medications by 40 percent to 50 percent, depending on the level of competition among drugmakers, a top executive at CVS Health Corp told Reuters. CVS is one of the largest U.S. pharmacy benefit managers and, along with rival Express Scripts, has put...

  • What!?! Specialty drug spending jumps 31% Tuesday, 10 Mar 2015 | 8:53 AM ET
    Prescription drugs

    Spending on prescription drugs in the U.S. rose 13.1% in 2014, the biggest increase in more than a decade, according a report from Express Scripts.

  • *FDA set to decide on approval of Novartis' Zarxio. LONDON/ LOS ANGELES, March 6- A revolution is brewing in healthcare with lower-cost copies of complex biotech drugs finally set to reach the United States, nine years after so-called biosimilars were launched in Europe. The first approval for a biosimilar in the United States is expected imminently- Zarxio,...

  • Three trades to go before the closing bell Wednesday, 4 Mar 2015 | 1:44 PM ET

    The "Halftime Report" traders give their final trades of the show.

  • Waiting for Yellen Q&A, but QE helping elsewhere Tuesday, 24 Feb 2015 | 10:21 AM ET
    The Federal Reserve building in Washington.

    As investors await word on U.S. interest rate increases, quantitative easing certainly seems to be helping stock markets in Europe and Japan.

  • Early movers: HD, CMCSA, TOL, ODP, JPM & more Tuesday, 24 Feb 2015 | 8:15 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • After-hours buzz: Express Scripts, SunPower & more Monday, 23 Feb 2015 | 5:21 PM ET
    Traders work on the floor of the New York Stock Exchange, Dec. 11, 2014.

    Check out which companies are making headlines after the bell Monday: Stifel, Express Scripts, SunPower & more.

  • US stocks close near highs ahead of Yellen testimony Monday, 23 Feb 2015 | 4:00 PM ET
    Traders work on the floor of the New York Stock Exchange Feb. 20, 2015.

    U.S. stocks pulled back from Friday's records to close narrowly mixed ahead of Fed Chair Janet Yellen's remarks over the next two days.

  • Wall Street uneasy after Greece deal; Yellen eyed Monday, 23 Feb 2015 | 8:25 AM ET
    Janet Yellen, Chair of the Federal Reserve.

    U.S. stock index futures signaled a lower open on Monday as uncertainty surrounded Greece's deal with its euro zone creditors.

  • Cramer's game plan: Expect major news on this Friday, 20 Feb 2015 | 6:15 PM ET
    Spanish Finance Minister Luis de Guindos, left, talks with Greek Finance Minister Yanis Varoufakis at a euro zone finance ministers meeting to discuss Athens' plans to reverse austerity measures, in Brussels, Feb. 20, 2015.

    With the Dow soaring to new highs, Jim Cramer is ready to do some buying in case the euphoria wears off.

  • US still the place to be: Delphi's Scott Black Friday, 20 Feb 2015 | 3:47 PM ET
    Traders work on the floor of the New York Stock Exchange Feb. 20, 2015.

    U.S. stocks are the place to be right now, Delphi's Scott Black said Friday on CNBC. Here's where he's putting his money.

  • Buffett's Berkshire builds Deere stake, dumps Exxon Wednesday, 18 Feb 2015 | 7:19 AM ET
    A John Deere 8600 tractor is displayed on opening day of the World Ag Expo on February 10, 2015 in Tulare, Calif.

    Warren Buffett's Berkshire Hathaway disclosed a 5 percent stake in Deere & Co. and said it shed a $3.74 billion investment in Exxon Mobil.

  • NEW YORK, Feb 17- Warren Buffett's Berkshire Hathaway Inc on Tuesday disclosed a 5 percent stake in agricultural equipment maker Deere& Co and said it shed a $3.74 billion investment in oil company Exxon Mobil Corp as oil prices plunged. The changes were among several that Berkshire made in its common stock investments in the fourth quarter, according to a U.S....

  • Drug price wars 'drive value': Medical exec Friday, 6 Feb 2015 | 5:21 PM ET
    Hepatitis C sufferers and supporters hold placards during a demonstration outside of US laboratory Gilead Sciences office in Madrid on February 5, 2015.

    Price cuts, which may hurt pharmaceutical margins, are fundamentally better for consumers, said Dr. Steve Miller of Express Scripts.

  • Pricing wars heat up over hepatitis C drugs Wednesday, 4 Feb 2015 | 12:13 PM ET
    A researcher works on a hepatitis C virus drug at Gilead Sciences lab in Foster City, Calif.

    Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.